Aiforia Technologies Plc initiated a path to secure regulatory approval for its first product in the United States. The Food and Drug Administration (FDA) is responsible for market surveillance of medical devices in the U.S. Together with a local consulting company, Aiforia is planning and implementing the necessary steps to submit an application to the FDA during 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.99 EUR | +0.50% | +1.79% | +14.33% |
May. 15 | Aiforia Wins a Framework Agreement to Provide AI Solutions for Fimlab Laboratories in Finland | CI |
Apr. 24 | Aiforia Signs A Contract with A Veterinary Health Company in the US | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.33% | 112M | |
+13.11% | 3,123B | |
+11.55% | 86.45B | |
+7.38% | 78.6B | |
-14.34% | 53.99B | |
+25.92% | 48.46B | |
-24.39% | 46.78B | |
+35.49% | 46.36B | |
+80.54% | 42.36B | |
-6.24% | 25.25B |
- Stock Market
- Equities
- AIFORIA Stock
- News Aiforia Technologies Oyj
- Aiforia Technologies Plc Initiates Path to Secure its First Regulatory Approval in the United States